Radiopharmaceutical firm Cytogen said today that a new phase I/II clinical study will be evaluating the utility of its ProstaScint prostate cancer agent in helping to guide radioimmunoguided intensity modulated radiation therapy (IMRT) procedures.
In the study, patients with positive lymph nodes will receive hormonal therapy in addition to radiation treatment, according to the Princeton, NJ-based vendor. Specific areas of greatest tumor burden within the prostate, as identified by the ProstaScint image, will receive boosted doses of radiation via IMRT, according to Cytogen.
By AuntMinnie.com staff writersJune 6, 2002
Related Reading
Cytogen raises $5 million, June 5, 2002
Cytogen brings BrachySeed Pd-103 to U.S., May 30, 2002
Cytogen reveals 2002 forecast, May 30, 2002
Cytogen to bring ProstaScint to Canada, March 18, 2002
Draxis Health turns in record Q1, May 16, 2002
Copyright © 2002 AuntMinnie.com
